Using low dose aspirin to prevent recurrent preterm birth
A Dose Escalation Study of Low Dose Aspirin for the Prevention of Recurrent Preterm Birth
This study is looking at how low doses of aspirin might help women who are at risk of having another preterm baby, by finding the best dose to prevent issues like preeclampsia and slow growth in the baby.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11111265 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of low dose aspirin in preventing recurrent preterm births among at-risk women. The study will involve a dose escalation approach, where different doses of aspirin will be tested to determine the optimal amount for preventing complications associated with preterm birth, such as preeclampsia and fetal growth restriction. Participants will be monitored closely throughout their pregnancy to assess the impact of the treatment on birth outcomes. The goal is to provide a safe and effective preventive strategy for women who have experienced preterm births in the past.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who have a history of preterm birth and are currently pregnant or planning to become pregnant.
Not a fit: Patients who have not experienced preterm birth or those with contraindications to aspirin use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of recurrent preterm births and improve outcomes for both mothers and their babies.
How similar studies have performed: Previous studies have shown promising results with low dose aspirin in reducing preterm birth rates, indicating that this approach has potential based on earlier findings.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Clifton, Rebecca Gersnoviez — George Washington University
- Study coordinator: Clifton, Rebecca Gersnoviez
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.